Ingrid Wertz is the executive director of Protein Homeostasis Center of Excellence at BMS. She and her team are responsible for developing protein degrader medicines for patients in need by harnessing degradation systems naturally present within the human body. Their aim is to specifically target and eliminate disease-relevant proteins that have been largely undruggable. Prior to joining Bristol Myers Squibb, Ingrid was a principal scientist in the departments of Discovery Oncology and Early Discovery Biochemistry at Genentech, where she led the company’s degrader platform aimed at co-opting ubiquitin system enzymes for therapeutic benefit.